AAOpt 2024: Alcon launches first ever one-week replacement contact lens, PRECISION7

News
Article

Broad commercial availability of the lens is expected in the beginning of January 2025.

Contact lenses demonstrated to patient Image credit: AdobeStock/Svitlana

Image credit: AdobeStock/Svitlana

Alcon has announced the launch of PRECISION7, a one-week replacement contact lens, in the US.1 The lens, which utilizes a 7-day ACTIV-FLO System that provides 16 hours of comfort and clear vision, is the only one-week replacement lens on the market, according to a news release.

“We are making history with the bold innovation of PRECISION7,” said Max Wolf, general manager and head of Vision Care and Contact Lenses at Alcon, in the release. “Now, patients can start and end every week fresh with a first of its kind contact lens featuring ACTIV-FLO technology. This is also the first time we are introducing both sphere and toric lenses to the US market simultaneously, allowing eye care professionals to address the needs of the majority of patients right away.”

Presicion7 contact lenses are the first weekly replacement lens on the market - Image courtesy of Alcon

Image courtesy of Alcon.

According to the release, more than half of new patients are being fit in reusable lenses due to cost consideration, even though almost 9 out of 10 eye care providers believe daily disposable lenses are better overall for their patients. A majority of optometrists also agree that a one-week contact lens replacement schedule may be a more intuitive option for their patients, in contrast to a 2-week replacement schedule.1

As for the workings of ACTIV-FLO, a combination of a moisturizing agent embedded in a lens matrix and a continually released proprietary replenishing agent act to moisturize the serafilcon A lens for 7 days.1

“Data show that 3 out of every 4 contact lens wearers want their eye care professionals to talk to them about new contact lens technology,” said Jason Compton, OD, FAAO. “When daily disposable lenses aren’t an option, PRECISION7 provides 16 hours of outstanding comfort and precise vision, even on day 7, at a price our patients can afford. It has an easy and intuitive replacement schedule that allows my patients to pick their preferred day of the week to replace their contact lenses.”

PRECISION7 has been launched as an addition to the Alcon WaterInnovations portfolio of contact lenses. While sphere and toric lenses are immediately available through select eye care providers in the US, broad commercial availability is expected in the beginning of January 2025. Markets outside the US will then follow.1

Reference:
  1. Alcon debuts groundbreaking PRECISION7, a one-week replacement contact lens to start and end every week fresh. Alcon. November 7, 2024. Accessed November 7, 2024.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
© 2025 MJH Life Sciences

All rights reserved.